Agnete Fredriksen Brunsvik

Title: Agnete Fredriksen Brunsvik: Innovator in Antibody-Based Therapeutics

Introduction

Agnete Fredriksen Brunsvik is a notable inventor based in Rælingen, Norway. She has made significant contributions to the field of immunology, particularly in the development of recombinant antibody-based molecules. Her work focuses on enhancing immune responses to combat diseases such as multiple myeloma and lymphoma.

Latest Patents

Agnete holds 1 patent for her innovative work on modified antibodies. The patent describes recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses. These molecules consist of at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Additionally, the patent includes nucleic acid molecules encoding the recombinant antibody-based molecule and methods for treating multiple myeloma or lymphoma in patients.

Career Highlights

Agnete is currently associated with Vaccibody AS, a company dedicated to advancing therapeutic vaccines. Her research and development efforts have positioned her as a key figure in the field of antibody engineering.

Collaborations

Agnete collaborates with esteemed colleagues such as Bjarne Bogen and Inger Sandlie, who contribute to her research endeavors and enhance the impact of her work.

Conclusion

Agnete Fredriksen Brunsvik's innovative contributions to antibody-based therapeutics exemplify her commitment to advancing medical science. Her work has the potential to significantly improve treatment options for patients suffering from serious conditions like multiple myeloma and lymphoma.